Technetium-99Combination Therapy In The Application Of Rheumatoid Arthritis

Background and purposeTo evaluate the efficacy and side effects of patients who were treated with99Tc-MDP, disease-modifying anti-rheumatic drugs and non-steroidal anti-inflammatory drug, and to guide clinical treatment.MethodsChoose89patients with rheumatoid arthritis, fulfilling American College of Rheumatology classification criteria of RA in1987. And diseases are all in the active stage, DAS28>3.2.99Tc-MDP group (50RA patients) treated with99Tc-MDP (0.15-0.2μg/d, continuous intravenous infusion of10-15d) combined disease-modifying anti-rheumatic drugs and non-steroidal anti-inflammatory drugs. Control group (39RA patients) only apply with disease-modifying anti-rheumatic drugs and non-steroidal anti-inflammatory drugs for treatment. Disease-modifying anti-rheumatic drugs including methotrexate (10mg/qw) and leflunomide (20mg/qd). Non-steroidal anti-inflammatory drugs meloxicam (15mg/qd), According to the condition of patients can be plus prednisone (lOmg/d) for7-10days.After the treatment of4weeks and12weeks, compared the efficacy and safety of the two groups.Results1. efficacy assessment (1) After4weeks,12weeks treatment, the improvement in tender joint count, swollen joint count, patient’s assessment of pain, patient and physician global assessment and the drop of erythrocyte sedimentation (ESR) were better in the99Tc-MDP group than that of control group, the difference was statistically significant (P<0.01).(2) After12weeks treatment, the proportion of patients achieving ACR20、 ACR50、ACR70in99Tc-MDP group was higher than that of control group, the difference was statistically significant (P<0.05). DAS28score of the two group were reduced compared with baseline (P<0.01), the decline of"Tc-MDP group was higher than the control group,(P<0.05)(3) At the end of week12, both groups have different number of patients achieving EULAR criteria. There are still significant statistical difference (P<0.05).2. safety assessmentThe total incidence of adverse events in this two treatment groups was not statistically significant.Conclusion1.99Tc-MDP group can significantly ease the conditions of rheumatoid arthritis patients, short-term treatment is better.2.99Tc-MDP group has good safety with short-term treatment of rheumatoid arthritis and found no serious adverse events.